Promising Alzheimer’s drug needs to be studied for safety, researchers say
An experimental Alzheimer’s drug moderately slowed the effects of the disease but was linked to patient safety risks that warrant longer clinical trials, according to a study published late Tuesday. But the detailed results also concluded that the drug, lecanemab, was associated with “adverse…
#drug #alzheimer #lecanemab #experimentalalzheimer #eisai #patients #drugmoderately #patient #studypublished #brain